Volition

Exhibitor

Volition is a pioneer in the application of epigenetics for drug discovery and development, particularly in diseases associated with Netosis, Oncology, Inflammation, Autoimmune and Neurodegenerative diseases. Our mission is to provide actionable insights that can significantly accelerate drug discovery and development projects, from drug screening, early-stage discovery to clinical trials. Our Nu.Q^® Discover assays have been validated in preclinical studies and clinical trials for their robustness in tracking epigenetic modifications and are being used to track changes in Histone PTM levels in a dose-dependent manner, providing real-time, quantitative insights into the mechanism of action of therapeutics. Additionally, we developed a distinct assay for quantifying NETs (Neutrophil Extracellular Traps), providing novel perspective across combination therapies and small molecules. NETosis markers are being developed for screening compound libraries for potential drug candidates that modulate NETosis. Our technology offers unmatched precision and scalability, and its sensitivity and specificity make it essential for both academic and pharmaceutical projects. We ensure all our assays meet industry standards, coming with CE markings, available as RUO kits or customizable prototypes following CLSI development guidelines.